Search

Researchers from Memorial Sloan Kettering Cancer Center (MSK), in collaboration with an international research team and the ECOG-ACRIN Cancer Research Group, have found that abbreviated breast magnetic resonance imaging (MRI) detected more cancers than digital breast tomosynthesis (3-D mammography) in average-risk women with dense breast tissue.

… Tuesday, February 25, 2020 Researchers from Memorial Sloan Kettering Cancer Center (MSK), in collaboration with an international research team and the ECOG-ACRIN Cancer Research Group , have found that abbreviated breast magnetic resonance imaging (MRI) detected more cancers than digital breast tomosynthesis

… Tuesday, June 25, 2024 The internet is full of “miracle cures” for cancer and alleged surefire ways to prevent it, and well-meaning people may urge cancer patients to just try them out in hopes of eliminating their disease. Some patients, worried that conventional treatments won’t work or pose significant

Practical tips for caregivers helping an older relative or friend make decisions about cancer treatment.

… Friday, November 25, 2016 Summary An older adult who is diagnosed with cancer may need help making treatment decisions. Our Geriatrics Service Chief discusses how to lend support. Highlights Decisions should be made based on each individual’s unique situation. It’s important to consider the goals of

A new paper from MSK physician-scientist Luis Diaz presents the evidence on which the FDA approved the immunotherapy drug pembrolizumab for cancers with a specific genetic abnormality.

… Friday, June 9, 2017 Two years ago at the annual meeting of the American Society of Clinical Oncology, researchers from Johns Hopkins wowed an audience with results from a recent immunotherapy clinical trial. People with a type of colorectal cancer that bore a genetic abnormality called mismatch repair

By sequencing the entire genome of a tumor, the experimental test will go beyond standard testing for common cancers in adults.

… Wednesday, May 18, 2022 DNA sequencing tests that look for mutations in cancer-associated genes have become the standard of care at leading centers, including at Memorial Sloan Kettering Cancer Center (MSK). MSK’s test, called MSK-IMPACT™, can detect mutations in 500-plus cancer-related genes. This information

For the first time, scientists have shown that the gene APC, which is mutated in the vast majority of colorectal cancers, might be a promising target for future therapies.

… Wednesday, July 1, 2015 Summary Working in mice, Memorial Sloan Kettering scientists have found that genetic alterations in the APC gene, which are found in more than 90 percent of colorectal cancers, play an important role in driving the disease. The researchers are now asking whether potential drugs

A recently approved treatment approach dramatically improves the outlook for people with an aggressive form of lymphoma.

… Friday, February 8, 2019 Summary People newly diagnosed with peripheral T cell lymphoma have traditionally been treated with chemotherapy. A recent study showed that adding a drug called brentuximab vedotin to chemotherapy could stop the disease from progressing and improve survival. Peripheral T cell

Three faculty members from Memorial Sloan Kettering Cancer Center (MSK) and Sloan Kettering Institute (SKI) have been elected to the 2021 class of American Association for the Advancement of Science (AAAS) Fellows.

… Thursday, January 27, 2022 Three faculty members from Memorial Sloan Kettering Cancer Center (MSK) and Sloan Kettering Institute (SKI) have been elected to the 2021 class of American Association for the Advancement of Science (AAAS) Fellows. The new class of AAAS Fellows includes 564 scientists, engineers

Researchers from Memorial Sloan Kettering Cancer Center (MSK) are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today, chimeric antigen receptor (CAR) T cells.

… Thursday, April 9, 2015 Researchers from Memorial Sloan Kettering Cancer Center (MSK) are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today

The combination immunotherapy of talimogene laherparepvec (T-VEC) and pembrolizumab met its primary endpoint of objective response rate at 24 weeks in our phase II clinical trial in patients with advanced sarcoma.

… Thursday, June 11, 2020 The combination immunotherapy of talimogene laherparepvec (T-VEC) and pembrolizumab met its primary endpoint of objective response rate at 24 weeks in our phase II clinical trial in patients with advanced sarcoma.  (1) The best objective response rate (ORR) was 30 percent (95%